Supplemental Methods
Reclassification analyses indicated an improvement in risk discrimination for the CV death/HF when including beta-CTx to a model including clinical variables and biomarkers (NRI at the event rate: 0.0207 (0.0002, 0.0412), continuous NRI: 0.1435 (0.0393, 0.2476), IDI 0.0045 (0.0006, 0.0085); Table S2 ). Similarly, the NR at the event rate indicated a significant improvement in reclassification for CV death (NRI at the event rate: 0.0214 (0.0065, 0.0363)) and all-cause mortality (NRI at the event rate: 0.1477 (0.1111, 0.1842); Table S2 ). Table S1 . Correlation matrix of all tested biomarkers displaying the Spearman correlation coefficients and respective p-values for Cterminal telopeptide, NT-proBNP, high-sensitivity troponin T, creatinine clearance, and the left ventricular ejection fraction. Model 1: age, sex, history of diabetes, prior MI, prior HF, revascularization during index hospitalization, TIMI risk score, and eGFR (modelled as a categorical variable <45, 45-<60, 60-<90, and ≥90 ml/min/1.73m 2
